BioSpace News Archive

Filters are connected in numerous phases during the manufacture of small molecular drugs, which is termed as active pharmaceutical ingredients, as well.

The EspeRare Foundation and the Pierre Fabre group announced today that the first patient in the EDELIFE clinical trial has received the three rounds of injection as planned.

Regulted information - Inside Information - Hyloris Pharmaceuticals SA announces that it has received a Complete Response Letter from the US Food and Drug Administration on its application for the US registration of Maxigesic IV®.

Nektar Therapeutics announced the promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer.

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), (“NRx Pharmaceuticals”), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authorization (EUA) for ZYESAMI® (aviptadil) for a sub-group of patients that in addition to ZYESAMI®, also received Remdesivir and continued to progress.

Endo International plc (NASDAQ: ENDP) today announced top-line results from its Phase 2 study of Collagenase Clostridium Histolyticum (or “CCH”) in participants with adhesive capsulitis (AC) of the shoulder, commonly known as “frozen shoulder.”

Wilmington, Delaware, United States, Transparency Market Research Inc.: Massive advancements in the biology and the life sciences sector coupled with the growing applications in numerous end-users have led to a bio-revolution around the world.

Emergex Vaccines Holding Limited announced that it has signed heads of terms for a collaboration with the Molecular Biology Institute of Paraná in Brazil.

Cytokinetics, Incorporated announced the pricing of its offering of $450.0 million aggregate principal amount of 3.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.